Medicinal chemistry strategies toward host targeting antiviral agents. Issue 5 (14th February 2020)

• Record Type: Journal Article
• Authors: Ji, Xingyue; Li, Zhuorong
• Is Part Of: Medicinal research reviews. Volume 40:Issue 5(2020)
• Page Start: 1519
• Page End: 1557
• Publication Date: 2020-02-14
• Subjects: broad‐spectrum antivirals -- direct‐acting antiviral agents -- drug resistance -- host targeting antiviral agents; Pharmacology -- Periodicals; Drugs -- Research -- Periodicals; 615
• DOI: 10.1002/med.21664
• Languages: English
• ISSNs: 0198-6325

Abstract

Abstract: Direct‐acting antiviral agents (DAAs) represent a class of drugs targeting viral proteins and have been demonstrated to be very successful in combating viral infections in clinic. However, DAAs suffer from several inherent limitations, including narrow‐spectrum antiviral profiles and liability to drug resistance, and hence there are still unmet needs in the treatment of viral infections. In comparison, host targeting antivirals (HTAs) target host factors for antiviral treatment. Since host proteins are probably broadly required for various viral infections, HTAs are not only perceived, but also demonstrated to exhibit broad‐spectrum antiviral activities. In addition, host proteins are not under the genetic control of viral genome, and hence HTAs possess much higher genetic barrier to drug resistance as compared with DAAs. In recent years, much progress has been made to the development of HTAs with the approval of chemokine receptor type 5 antagonist maraviroc for human immunodeficiency virus treatment and more in the pipeline for other viral infections. In this review, we summarize various host proteins as antiviral targets from a medicinal chemistry prospective. Challenges and issues associated with HTAs are also discussed.